Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Upper Tract Urothelial Carcinomas × infigratinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Upper Tract Urothelial Carcinomas 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Renal Pelvis and Ureter Urothelial Carcinoma 1 Papillomavirus Infections 1 Nasopharyngeal Neoplasms 1 Hematologic Neoplasms 1 Glioma 1 Glioblastoma 1 Cholangiocarcinoma 1

Interventions

infigratinib 1 Drug Evaluation 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04197986 2024-03-13

PROOF302

QED Therapeutics, a BridgeBio company

Phase 3 Terminated

39 enrolled 31 charts

Upper Tract Urothelial Carcinomas

Data powered by HemOnc (CC BY 4.0) Colophon ⚡